C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 1.47 EUR 1.38% Market Closed
Market Cap: 6B EUR

China Medical System Holdings Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Medical System Holdings Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
SWB:2M7C
Interest Income Expense
¥269.2m
CAGR 3-Years
217%
CAGR 5-Years
23%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Interest Income Expense
HK$392.8m
CAGR 3-Years
N/A
CAGR 5-Years
54%
CAGR 10-Years
N/A
U
United Laboratories International Holdings Ltd
HKEX:3933
Interest Income Expense
¥240.7m
CAGR 3-Years
157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sino Biopharmaceutical Ltd
HKEX:1177
Interest Income Expense
¥2.8B
CAGR 3-Years
-43%
CAGR 5-Years
49%
CAGR 10-Years
18%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Interest Income Expense
-HK$1.1B
CAGR 3-Years
5%
CAGR 5-Years
18%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Interest Income Expense
$513.2m
CAGR 3-Years
116%
CAGR 5-Years
64%
CAGR 10-Years
31%
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
6B EUR
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.

2M7C Intrinsic Value
1.16 EUR
Overvaluation 21%
Intrinsic Value
Price
C

See Also

What is China Medical System Holdings Ltd's Interest Income Expense?
Interest Income Expense
269.2m CNY

Based on the financial report for Jun 30, 2025, China Medical System Holdings Ltd's Interest Income Expense amounts to 269.2m CNY.

What is China Medical System Holdings Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
23%

Over the last year, the Interest Income Expense growth was 12%. The average annual Interest Income Expense growth rates for China Medical System Holdings Ltd have been 217% over the past three years , 23% over the past five years .

Back to Top